Licensing deal for Coniel
By Gong Si |
October 23, 2013, Wednesday
|
Print Edition
Print Edition
Bristol-Myers Squibb Company yesterday said it has entered into a licensing agreement with Kyowa Hakko Kirin Co Ltd for the exclusive rights in China to commercialize Coniel, a calcium channel blocker for the treatment of hypertension and angina pectoris. This is the first China-specific in-licensing transaction under the company’s business development strategy in China, and an example of the company’s long-term commitment to its presence in China. Coniel was previously marketed in China by Kyowa Hakko Kirin. Additional details of the agreement were not disclosed.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 沪ICP证：沪ICP备05050403号-1
- |
- 互联网新闻信息服务许可证：31120180004
- |
- 网络视听许可证：0909346
- |
- 广播电视节目制作许可证：沪字第354号
- |
- 增值电信业务经营许可证：沪B2-20120012
Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
